Background
Ustekinumab with trade name Stelara, is an FDA-approved drug to Crohn's disease, Ulcerative Colitis, Plaque Psoriasis and Psoriatic Arthritis, targeting both interleukins (IL)-12 and IL-23. Ustekinumab is a fully human immunoglobulin G1 kappa mAb that binds to IL-12 and IL-23. Ustekinumab binds to the p40 subunit common to IL-12 and IL-23 and prevents their interaction with the IL-12 receptor β1 subunit of the IL-12 and IL-23 receptor complexes, thereby disrupting the proinflammatory pathway. Antibodysystem Anti-Ustekinumab Antibody, pAb, Rabbit is produced from sera of a rabbit immunized with Ustekinumab.